Recent Company News

• 08:58 AM ET Jul 10, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:49 AM ET Jul 10, 2025
  

  Pfizer and Astellas (4503.JP) announce topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study ($25.56, 0.00)

• 07:36 PM ET Jul 09, 2025
  

  Astellas Pharma reports preliminary Q1 U.S. sales of IZERVAY $110M ( ¥15.9B) (¥1386.0000, 0)

• 07:44 PM ET Jul 07, 2025
  

  Astellas Pharma downgraded to neutral from buy at Mizuho Securities (¥1382.0000, 0)

• 10:47 AM ET Jun 24, 2025
  

  CDP ocean questions; ESMA ratings rule consultation; GRI Sustainable Taxonomy among ESG products & ratings highlights May-Jun

• 01:24 PM ET May 30, 2025
  

  New XOFIGO (radium-223 dichloride) data in metastatic castration-resistant prostate cancer from Phase III PEACE III trial published in Annals of Oncology (€24.74, 0.00)

• 07:53 PM ET May 29, 2025
  

  Astellas Pharma, Evopoint Biosciences enter exclusive license agreement for XNW27011 (¥1413.5000, 0)

• 04:04 PM ET May 28, 2025
  

  Taysha Gene Therapies announces pivotal Part B trial design details for TSHA-102 in Rett syndrome ($2.44, 0.00)

• 05:11 PM ET May 22, 2025
  

  Astellas Pharma and Pfizer report longer-term follow-up results from open-label extension of Phase 3 ARCHES study (¥1390.5000, 0)

• 02:09 AM ET May 12, 2025
  

  Asia pharma stocks under pressure as Trump eyes executive order cutting drug prices: